The government has suggested weight-loss drugs could boost the economy by helping obese people in England get back to work. But NHS experts have warned treatment services are already overstretched trying to deal with unprecedented demand from patients wanting these drugs.

What health experts think of the growing Ozempic “microdosing” trend that claims taking very small doses of GLP-1 drugs can still help people lose weight with fewer side effects at a lower cost.

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is typically more affordable than Wegovy. At the time of publishing, the list price for Ozempic was $968.52 per month, whereas the list price for Wegovy was $1,349.02 per month. List prices are the price set by the manufacturer.

As for why it’s not approved for weight loss in the UK, Dr Kayat added: “It works by helping to regulate your appetite and reduce cravings and hunger. But in the UK, it’s only supposed to be used for type 2 diabetes, and that’s in order to try and protect the resources for the type 2 diabetics.”

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

A new study suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss, may help reduce the risk of overdose and alcohol intoxication in people with